Appetite and fullness
Studies investigate how hormonal signaling changes hunger and fullness.

Research Products
Retatrutide · 30mg
In Stock · SKU RT30
Retatrutide is an experimental compound being studied for its effects on appetite, blood sugar and the way the body uses energy. Researchers are interested in it because it acts on three hormone receptors rather than just one. It is not approved for human use.
For laboratory research only. Not for human consumption or medical use. Published research does not establish the safety or identity of a specific supplied vial.
Research explained
Retatrutide is an experimental compound being studied for its effects on appetite, blood sugar and the way the body uses energy. Researchers are interested in it because it acts on three hormone receptors rather than just one. It is not approved for human use.
The compound activates three receptors: GLP-1, GIP and glucagon. Together, these signaling pathways play roles in appetite, blood glucose regulation and energy metabolism. Activating all three is being investigated in controlled research.
Product-specific details are from the Vendure catalog. Purity and testing claims should only be used when backed by batch-specific evidence.
Mechanism and research areas
Studies investigate how hormonal signaling changes hunger and fullness.
Researchers examine how these receptors influence glucose and insulin-related responses.
Experiments explore how adding glucagon-receptor activity changes energy regulation.
Published research
A randomized phase 2 study enrolled 338 adults with obesity or overweight and a weight-related condition. After 48 weeks, the 12 mg investigational-treatment group had an estimated average 24.2% reduction in body weight, compared with 2.1% in the placebo group.
The trial tested investigational pharmaceutical material under medical supervision. Gastrointestinal side effects were common and increases in heart rate were observed. These results do not establish the quality, safety or effect of a retail research vial, and they are not instructions for use.
Randomized, double-blind, placebo-controlled phase 2 clinical trial · 2023
Jastreboff AM et al. · New England Journal of Medicine · DOI: 10.1056/NEJMoa2301972
Reported dose-dependent changes in average body weight over 48 weeks in a controlled investigational trial.
Limitations: Safety follow-up was limited; pharmaceutical clinical-trial material is not equivalent to a commercial research sample.
Read original publicationQuality documentation
Certificates of analysis must be matched to a specific batch. No test result, purity figure or third-party verification is implied unless the corresponding document is provided.
Ask about batch documentation →